US No Surprises Act (42 USC 300gg-111 to 300gg-139) and 45 CFR Part 149 149.740: Include in the RxDC report the plan-level identifiers, enrollment, top-50 drug lists, total spending by category, premiums, and rebates by therapeutic class and top-25 drugs

The report must give, per plan or coverage, identifying information, plan year dates, enrollment on the last day of the reference year and the States of offering; and per State and market segment the 50 brand drugs most frequently dispensed, the 50 most costly drugs and the 50 drugs with the greatest spending increase (each with spending, participant counts, dosage units and paid claims), total annual spending split between hospital, primary and specialty care, pharmacy-benefit and medical-benefit drugs and other costs, average monthly premiums paid by employers and by enrollees with total premium and life-years, prescription drug rebates, fees and other remuneration (including the spread between amounts paid to and by the PBM) by therapeutic class and for the 25 drugs with the largest rebates, the allocation method and the effect of rebates on premiums and cost sharing.